Diabetes mellitus (DM) is a chronic disease that can affect metabolism of glucose and other metabolites. In this study, the normaland obese-diabetic rats were compared to understand the diabetes disorders of type 1 and 2 diabetes mellitus. This was done by evaluating their urine metabolites using proton nuclear magnetic resonance ( 1 H NMR)-based metabolomics and comparing with controls at different time points, considering the induction periods of obesity and diabetes. The biochemical parameters of the serum were also investigated. The obese-diabetic model was developed by feeding the rats a high-fat diet and inducing diabetic conditions with a low dose of streptozotocin (STZ) (25 mg/kg bw). However, the normal rats were induced by a high dose of STZ (55 mg/kg bw). A partial least squares discriminant analysis (PLS-DA) model showed the biomarkers of both DM types compared to control. The synthesis and degradation of ketone bodies, tricarboxylic (TCA) cycles, and amino acid pathways were the ones most involved in the variation with the highest impact. The diabetic groups also exhibited a noticeable increase in the plasma glucose level and lipid profile disorders compared to the control. There was also an increase in the plasma cholesterol and low-density lipoprotein (LDL) levels and a decline in the high-density lipoprotein (HDL) of diabetic rats. The normaldiabetic rats exhibited the highest effect of all parameters compared to the obese-diabetic rats in the advancement of the DM period. This finding can build a platform to understand the metabolic and biochemical complications of both types of DM and can generate ideas for finding targeted drugs. 
Introduction
Diabetes mellitus (DM) is a very complex disease, which is characterized by the rise of blood glucose level and consequently to the resistance of insulin and failure of pancreatic function [6] . There are two types of DM; in type 1, the pancreas does not produce enough insulin, and in type 2, the body is unable to use the insulin effectively. The fluctuation of blood glucose levels can affect vessels and metabolites. This fluctuation may also result in several serious complications and cause other related chronic diseases. The development of diabetes as a complex phenotype is associated with weakness of the insulin secretion and an increase in glucose production as well as resistance to insulin action or production. These factors might have a direct contribution to the progress of DM [2, 6, 8, 9, 25] . The exact mechanisms of these factors and their interactions in generating glucose intolerance and other metabolites for DM are still unclear. It has been proposed that the ultimate pathway in the development of DM is the perturbation of pancreas β cells action in compensating insulin resistance [32] . Many efforts have been made to evaluate the glycemic control and DM model as well as the associated complications. Numerous hypoglycemic agents have been adopted, including biguanides (phenformin, buformin and, metformin). However, phenformin and buformin have been banned due to their association with lactic acidosis [11] . Therefore, metformin is currently the only biguanide commercially available for use.
Several studies have provided comprehensive insights on the metabolic complications and changes associated with diabetes and obesity as well as their correlations [29] . However, many factors have profound effects on the reported results, including the environment, animal type, age, gender, and diet source as well as potential maladies. The analytical tool used in the analysis can also lead to some contradiction or variations of findings [33] . Animal models may show a vital role in enlightening the mechanism associated with diabetes and its metabolic disorders [3, 7, 8] . Various experimental works have been implemented to understand the molecular events associated with this disease and its metabolic disturbances [21] [22] [23] . The aim of systems biology is to accomplish a systematic assessment of biological variations in an organism that are related to disease complications. The changes can be evaluated by measuring the level of metabolites and can also be analyzed via an advanced multivariate data analysis approach to view the patterns. The complexity of the experimental data and statistical results also present opportunity to more vigorously describe the mechanisms that explain these changes. Moreover, the broad selection provided the regarding measurements and metabolites might offer better extrapolative ability about outcomes compared to a single biomarker or parameter. Recently, numerous omics approaches have been performed to determine the prognostic biomarkers of DM [3, 7, 8, 16] . In recent decades, metabolomics has become as one of the techniques used in the study of traditional medicine via a holistic approach [31] . Our current study is focusing on the metabolomics approach to measure metabolite changes. This approach can be useful in identifying aspirant biomarkers of DM and validating the existing ones. In most metabolomics studies, animal models have normally been applied to study the mechanism of type 2 DM and determine the biomarkers. Clinicians and researchers have mostly used biofluids to evaluate the diagnosis and symptoms of diabetes [30] . Many molecules can be identified from the association of biochemical systems with the pathways of cellular and systemic biology. These molecules are either chemical substrates or bioproducts, such as carbohydrates, fatty acids, or amino acids, which are the metabolites involved in the physiological functions of organism's cells.
For a comprehensive study of DM and its complications, several studies have recently been conducted via animal models [2, 6, 8, 9] . Streptozotocin is widely used as a valuable agent for diabetes production because it has the ability to allow steady diabetic progression with minor, moderate, or serious hyperglycemia. For inducing type 1 DM conditions, a higher dose of STZ is usually used, ranging from 50 to 60 mg/kg compared to type 2 with a low STZ dose from 20 to 30 mg/kg. However, it is still confusing whether these doses are really representing type 1 and type 2 DM. In addition, the modified diet is used to stimulate obesity and diabetes conditions in type 2 DM [8] .
Not many studies have been conducted to study the differences between normal diabetes and obese diabetes in SpragueDawley rat model and their complications in prolonged time. Therefore, this study was implemented to fill in the gap about the complications associated with type 1 and type 2 DM on the urine composition of obese-and normal-diabetic rats as well as the effect of metformin treatment on both models. The 1 H NMR-based metabolomics of urine and biochemical results of serum obtained from these findings can provide a useful platform, regarding the mechanisms of normal diabetes and obese diabetes. It is known that obesity has a strong relationship with DM as it has an essential role in many metabolic disorders. However, the precise mechanism of this relationship is still poorly understood.
Materials and methods

Chemicals and reagents
Among the used chemicals and reagents in this study, potassium dihydrogen phosphate (KH 2 PO 4 ), deuterated methanold4 (CH 3 OH-d 4 ), sodium deuterium oxide (NaOD), deuterium oxide (D 2 O), and trimethylsilyl propionic acid-d 4 sodium salt (TSP) were purchased from Merck (Darmstadt, Germany). The other chemicals include streptozotocin (STZ), carboxymethyl cellulose (CMC), sodium azide, and metformin were obtained from Sigma-Aldrich (St. Louis, MO, USA). Concerning the rats' food, normal chow and high-fat diet ingredients were supplied by Gold Coin (Kuala Lumpur, Malaysia).
Animal disease model
An established protocol for diabetic rat model was followed as practiced in the Faculty of Medicine and Health Sciences, Universiti Putra Malaysia [12] . The approval of animal ethics for using and handling of the rats was given by the Animal Care and Use Committee of the Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM/FPSK/ PADS/BR-UUH/00493). Male Sprague-Dawley (SD) rats (5 weeks old) obtained from Chenur Supplier (Selangor, Malaysia) were used to conduct the in vivo experiments. The range of their weights was between 150 to 200 g. The rats were comfortably kept in an animal house in appropriate cages. Conditions for a regular and stress-free living were provided, including a convenient temperature (20-25°C), suitable relative humidity (55-60%), and standard light cycle (12-h light/dark). In the beginning of the study, the rats were acclimatized to the environment for 1 week. Free accessibility to food and water was sustained until the end of the study.
Induction of obesity and diabetes in rats and metformin treatment
After the adaptation period, the rats were randomly grouped into the normal diet (ND) and obese (OB) groups. The ND group received regular chow diet, and the OB ones were fed a high-fat diet (HFD), which was prepared thrice weekly in the processing laboratory of the Faculty of Food Science and Technology. The regular chow diet contains 126, 244, and 100 kcal of fat, carbohydrate, and protein, respectively. The HFD consists of 441, 128, and 76 kcal from fat, carbohydrate, and protein, respectively. After 12 weeks of significant obesity induction, the rats were again grouped, following a systematic method, and the diabetic groups were intravenously injected after overnight fasting with STZ. The STZ doses were 25 and 55 mg/kg per body weight for the obese-and normal-diabetic groups, respectively. After 3 days of diabetes induction, the fasting blood glucose levels were checked using a glucometer (Accu-chek Performa, Roche, Mannheim, Germany) by pricking the tail tip and rats with at least 13 mmol/L of blood glucose levels were considered significantly induced [17] . These rats were further carried out for pharmacological assays. In this study, the rats were fed with their respective diets until the end of the experiments. The treatment of the diabetic rats was tested after 1 week of STZ injections. Accordingly, all the rats were force-fed with CMC, except for the group treated with metformin (dissolved in 0.03% CMC). The fasting blood glucose level was measured weekly after overnight fasting for all the groups as detailed below.
1. ND-rats force-fed with 0.03% CMC, 2. NDSTZ-ND rats + STZ (55 mg/kg bw) force-fed with 0.03% CMC, 3. NDSTZ-MET-ND rats + STZ (55 mg/kg bw) force-fed with 150 mg/kg of metformin, 4. OB-rats force-fed with 0.03% CMC, 5. OBSTZ-OB rats + STZ (25 mg/kg bw) force-fed with 0.03% CMC, and 6. OBSTZ-MET-OB rats + STZ (25 mg/kg bw) force-fed with 150 mg/kg of metformin.
H NMR preparation and analysis of urine
The urine was collected by individually placing the rats in metabolic cages. The collection had been performed in tubes with 0.1% sodium azide to avoid bacterial contamination. The excreted urine volume was recorded and stored at − 80°C before being subjected to NMR analysis. The timelines for the urine collection were at week 12 (significant obesity induction; initial I), week 13 (diabetes induction; baseline B), and week 17 (after treatment period; final F). The NMR preparation and analysis procedures were performed, following the previously described protocol [5] . For preparation, the urine samples were thawed before being subjected to centrifugation at 5000 rpm for 5 min. Next, 400 μL of supernatant was transferred to Eppendorf tubes and 200 μL of KH 2 PO 4 buffer in D 2 O (pH 7.4), containing 0.1% TSP was added. The tubes were vortexed and centrifuged again at 13000 rpm for 10 min. Then, 550 μL of the supernatant was transferred to an NMR tube before being subjected to 1 H NMR analysis. The analysis was performed with 500 MHz NMR (Varian Inc., California, USA). This analysis was conducted with presat setting for each 1 H NMR, consisting of 64 scans in an acquisition time of 3.53 min. Moreover, two-dimensional (2D) J-resolved NMR was also performed to solve the overlapping signals of metabolites. For metabolite identification, the library of Chenomx NMR Suite (v. 6.2, Alberta, Canada) and the free online Human Metabolome Database (HMDB) as well as the previous reported data were used. The multivariate data analysis (MVDA) may exhibit the typical metabolites for each group of rats, allowing unique biomarkers related to diabetes and its mechanism of action to be identified.
Blood collection and biochemical analysis of serum
The previously mentioned timelines (initial, baseline, and final) for the urine collection were followed for the serum collection used for biochemical analyses. The initial and baseline blood collection followed the retro-orbital sampling technique by subjecting the rats to general anesthesia with ether. Then, soft penetration to the orbital sinus of the eye was performed using a clean capillary tube. In addition, the final blood collection was performed by cardiac puncture after anesthetizing the rats with ether. To obtain the serum, the blood collection was performed in sterile tubes; the blood was allowed to be separated for 1 h, followed by centrifugation at 6000 g for 10 min at 4°C. The supernatant was transferred into a sterile tube and stored at − 80°C prior to analysis. The rats' serum was tested for biochemical parameters with commercial kits obtained from Spinreact (Gerona, Spain) as previously reported [12] . Different types of biochemical parameters were measured, including cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), total triglycerides (TG), kidney function tests (creatinine), and blood glucose (OneTouch Basic glucose monitor, LifeScan).
Statistical analysis
The NMR spectra were equally binned into 365 points. The binning of the spectra was conducted into δ 0.04. The TSP signal was used to normalize the NMR spectra. The signals of urea (δ 5.55-5.95) and water (δ 4.60-4.85) were excluded from the dataset. In addition, the overlapped signal region of sugar (δ 4.50-5.14) was also removed, as it was previously reported to be a biomarker for diabetes. For conducting MVDA, the NMR chemical signals were considered as X variables, where the rats' groups were the observation. The NMR data were subjected to MVDA using the Simca-P software 13 (Umeå, Sweden) to determine the variation between the groups. Moreover, the Pareto was applied as a scaling method for all metabolites to have the same importance and to reduce the noise effects [1] . The relative quantification and significance of difference among the individual metabolites were evaluated using the InStat V2.02 statistical package (GraphPad Software, San Diego, CA, USA). In addition, the heat map for correlation and hierarchical clustering analysis (HCA) along with variable important in the projection (VIP) were implemented using MetaboAnalyst 2.5 as a free online metabolomics analysis software (http://www.metaboanalyst. ca). The prediction and validation abilities of the models were also evaluated by checking the regression value (R 2 ) as well the permutation test.
Results and discussion
Body weight
Obesity and diabetes are recognized as being associated with several similar causes. The disorders in both obesity and diabetes are often related, and the main cause of type 2 DM is obesity [3] . Obesity was induced in the rats prior to the evaluation of the diabetic effect and the metformin treatment. The changes among normal (ND), normal-diabetic, obese (OB), and obese-diabetic rats were first observed by comparing their weights and biochemical parameters. The changes were first compared between the OB and ND rats. When comparing the ND and OB rats, starting from week 6, there was a significant difference in their body weights. At week 12 (inducing obesity), the body weights of both groups were significantly (P < 0.05) different (Fig. S1a) . There was about 20% of increase in weight between OB and ND rats. This is in line with the previous study, which showed weight increment between the two groups after 12 weeks of HFD and decreased in weight after diabetes induction [12] . This study was built on changes in the lipid profiles and other biochemical parameters that use a HFD, including 49% of the total calories being from corn oil and pure ghee, supporting the theory that corn-based high-fat diets mimic the model of metabolic disorders of human obesity in rodents. In particular, studies have shown that a hydrogenated corn oil-based HFD can cause increased weight gain and hyperlipidemia in rats [15] . From the established results and the increase in body weight, it can be concluded that HFD-induced obesity was successfully achieved in male Sprague-Dawley rats after a feeding period of 12 weeks. Thus, the rats were divided into experimental groups prior to STZ induction.
The body weights of the OB and ND rats increased throughout the study, while the weights of the rats treated with metformin were steadily maintained with nonsignificant change (Fig. S1b) . The diabetic rats showed the lowest weights, which decreased drastically after STZ induction followed by the group treated with metformin compared to ND and OB groups. The possible explanation of this is that fat and protein catabolism to provide energy for the cells might be the reason for the dramatic decrease in body weight in obese-diabetes rats [24] . It can also be due to the increase in catabolic reactions, which lead to muscle wasting [24] . The body weight of obese-diabetic rats was improved with metformin treatment, which might be a reason for the regulation of the hyperglycemia state. The stabilized blood glucose level of the OB, ND, and treated diabetic rats could also maintain the steady body weight.
Analysis of urine of high-fat diet compared to normal diet rats
The influence of HFD on metabolite differences was investigated by comparing OB with ND groups at 12 weeks of obesity induction. Visually from the 1D and 2D-NMR, the primary variations in the OB groups were the rise of the level of alanine, acetate, pyruvate, malonate, creatine, allantoin, lactate, and formate compared to the ND groups. However, there was a decrease in the level of glucose, citrate, choline, and β-hydroxybutyrate. The PCA score plot showed a clear separation between the OB and ND rats (Fig. S2A) . The loading score plot showed that the OB group was separated due to their high content of alanine, acetate, pyruvate, malonate, creatine, allantoin, lactate, and formate (Fig. S2B) . However, the ND group had high contents of glucose, choline, trimethylamine, hippurate, and citrate. The urine of the OB group contains many of these metabolites due to the excessive concentration on the body or the production of other metabolites, which are synthesized from lipids. For instance, creatinine is the metabolite of creatine metabolism and taurine is the metabolite of lipid metabolism, whereas N -Nphenylacetylglycine is the biomarker for phospholipidosis [14, 28] . The accumulation of pyruvate in OB rats could potentially be due to the inhibition of pyruvate dehydrogenase by acetyl-CoA, which can be obtained from fatty acid breakdown via β-oxidation [13] .
There are different sources of energy in biological systems, which include the ketone bodies (acetoacetate, β-hydroxybutyrate, and acetone) that are synthesized from acetyl-CoA in the liver, especially during starvation. Furthermore, a diet that is extremely high in fat and low in carbohydrates also increases ketone bodies [4, 22] , which is in agreement with our results showing an increase in the levels of acetate and β-hydroxybutyrate in the OB rats. Among the three enzymes observed, hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme synthase (mHS) is involved in the control of ketogenesis and is expected to increase significantly in this study due to the HFD [22, 26] .
Biomarkers for normal, obese, and obese-diabetic rats
Based on the chemical shift data of the standard compounds available in the Chenomx library, the metabolites identified included glucose, pyruvate, lactate, citrate, fumarate, succinate, 2-oxoglutarate, β-hydroxybutyrate, acetoacetate, acetone, acetate, dimethylglycine, malonate, alanine, hippurate, creatinine, dimethylamine, trimethylamine, allantoin, formate, taurine, and creatine. Other identified metabolites were similar for both normal and obese rats. The supervised orthogonal projection to latent structurediscriminant analysis (OPLS-DA) was further applied to reveal clear observations about the significant metabolites associated with the ND and OB rats (Fig. 1a, b) .
There was an obvious separation between ND and OB with great class discriminant statistical values of R2 and Q2 of 98.5 and 96.8, respectively. This result provides the suggested metabolites (1-methylnicotinamide, creatine, allantoin, pyruvate, acetoacetate, acetone, and alanine) that significantly affected and changed by HFD. The S-plot is the covariance and correlation loading diagnostics of the OPLS-DA model, which offers an overview of the affecting variables on the model and filters important metabolites in the projection (Fig. 1c, d ). The significantly increased metabolites in OB rats are in the upper-right quadrant of S-plot, which have the positive correlation and covariance as shown in Fig. 1d . However, the decreased ones are in the lower-left quadrant. The urine results are shown for normal, obese, and obese-diabetic rats.
There was clear separation between both the obesediabetic and the ND groups. These groups are separated because of the difference in the content of metabolites. Metabolites such as citrate, fumarate, succinate, 2-oxoglutarate, formate, acetate, malonate, hippurate, and creatinine contributed to the separation of the OB from the ND groups. On the other hand, differences in acetone, taurine, alanine, dimethylamine, and allantoin were observed in addition to glucose, pyruvate, lactate, β-hydroxybutyrate, acetoacetate, creatinine, and trimethylamine between these two groups. A comparison between ND and obese-diabetic rats indicated that glucose, taurine, choline, and creatine were the biomarkers in the obese-diabetic group, which was shown in a shared and unique structure (SUS) plot (Fig. S3) . Other metabolite levels in the obese-diabetic rats were low and were close to the ND ones. The significant differences between the obese and obese-diabetic rats were observed with the increase of glucose, taurine, choline, and creatine and the reduction of pyruvate, acetoacetate, and acetate in the obese-diabetic groups. This result is due to the complication associated with DM being highly correlated to glucose metabolism.
Metabolic variation among normal, normal-diabetic, and obese-diabetic rats
The metabolic variations among normal-and obesediabetic rats and controls were identified for the urine spectra at week 13 of DM induction and week 17 after the treatment period. Two PCA models were performed separately to compare the diabetic rats with controls at week 13 (baseline) and 17 (final) as shown in Fig. 2 . The corresponding PCA score and loading column plots for these models are shown in Fig. 2 . Both score plots showed a distinctive cluster of normal-and obesediabetic groups from OB and ND of PC1, separating the healthy rats from the diabetic ones. The dominant metabolites in the normal-and obese-diabetic groups were glucose, creatine, taurine, and choline for both timelines. The other identified metabolites were apparently higher in the non-diabetic rats. Prior to the STZ induction, the levels of dominant metabolites in both normal-and obese-diabetic rats remain high during the period of 4 weeks. In addition, the elevation of glucose in both diabetic groups may cause the same metabolic and biochemical complications due to the non-treatment of diabetes.
For further clarification and the detection of biomarkers in both diabetic groups, OPLSDA of the two models was applied (Fig. 3) . The convenience of S and SUS plots in biomarker identification was valuable to compare both diabetic groups with the ND group. Again, at week 17, both the normal-and obesediabetic rats shared a higher content of glucose, creatine, taurine, and choline compared to normal rats as shown in Fig. 3c and Fig. S4 . The accumulation of creatine, taurine, and choline is most likely caused by the link to glucose metabolism and the possible development of cellular dysfunctions in diabetes. The high extracellular glucose level in diabetes may disturb the cellular regulation of these metabolites, which can have role in the progress of diabetic problems [26] . these findings, it is also proposed that the involved biochemical pathways in the changes of normal diabetes and obese diabetes are closely related and are all due to the disturbance of glucose metabolism. Another specific comparison between both diabetic groups and the ND group was conducted in order to see the metabolites contributing to the discrimination, which is shown in the PLSDA model (Fig. 4) . From the PLSDA score plot, we can observe that obese-and normal-diabetic groups were separated from the ND ones at week 17 (Fig.  4a) . The loading column plot showed that diabetic rats had higher levels of taurine, choline, glucose, and creatine than ND in accordance with the above results (Fig. 4b) . By conducting a 1-1 analysis of normal-and obese-diabetic rats, the normal-diabetic rats were obviously separated by their high contents of glucose, creatine, choline, glycerol, 2-oxoglutarate, N-N-phenylacetylglycine, dimethylamine, succinate, and allantoin, and a decrease of other metabolites. F u r t h er m o r e , t he a c et o ac e t a t e , a ce t at e , a n d β -hydroxybutyrate contents were significantly higher in normal-diabetic rats than in obese diabetic at week 17. For the identification of the most significant contributing variables, the VIP analysis of the PLS-DA model was considered (Fig. 4c) . A total of 19 metabolites significantly contributed to the discrimination among the diabetic groups and the ND group with VIP values of at least 0.5.
Metformin treatment
Although both normal-and obese-diabetic groups displayed higher glucose levels than the normal group, additional authentication was conducted by treating these rats with a standard drug (metformin) to check its sensitivity to normal diabetes and/or obese diabetes conditions. The PCA score plots obtained from the 1 H NMR spectra of the urine samples for both normal-and obese-diabetic rats were compared to assess the trajectory of metformin treatment (4 weeks). The score plots of the trajectories of metformin treatment for both models are shown in Fig. S5A and B. The trajectories of metformin after 4 weeks of treatment showed clear movement away from the diabetic rats. However, the treatment with metformin for obese-diabetic rats seems more effective because the movement of datasets of the treated rats was towards the healthy rats and closer to the initial group before injecting STZ. One possible explanation is that metformin is an oral drug for type 2 DM, which the mechanism of action is related to this obese diabetes rather than to normal diabetes.
For confirmation and validation of the metformin effect as an obese diabetes, the obese-diabetic rats were further evaluated. The PCA score and loading plots of metformin after treatment are shown in Fig. 5a, b . A total variance of 70.5% is described by PC1 and 2. The normal-and obese-diabetic metformin groups before treatment were clustered together on the left side of the score plot. However, the clear separation of obese-diabetic rats treated with metformin was observed after the treatment period. A scrutiny of the loading plot showed that the left cluster was discriminated from the right cluster by high glucose levels. The treatment with metformin was able to shift the obese-diabetic treated group to the right side, close to the ND and OB control groups, indicating the lowering of the glucose levels in the rats. The discriminating factor here was the high concentration of formate and fumarate in the obese-diabetic metformin group at the end of the study.
Biochemical analysis
The levels of fasting serum triglyceride, cholesterol, HDL, LDL, and glucose were analyzed comparing both normal-and obese-diabetic groups with ND and OB as well as the diabetic treated groups (Fig. 6 ). To investigate the impact of metformin on the lipid profile, the measurement of the levels of blood glucose, creatinine, triglyceride, LDL, and HDL was performed. It was obvious that the levels of creatinine, triglyceride, and LDL were remarkably high in normal and obese diabetes compared to control OB and ND, but not HDL. However, for the treated groups with metformin, the levels of these parameters were improved by the treatment. The explanation for this improvement is that metformin may possibly prevent hyperlipidemia by decreasing the accumulation of lipids [11, 19] . It is obvious that the blood glucose levels after STZ injection in the normal-and obese-diabetes groups were higher than in the ND control group and continued to rise for non-treated groups during the 4 weeks of the treatment period. Both normal-and obese-diabetes groups treated with metformin exhibited a reduction in blood glucose following the metformin treatment period of 4 weeks and tended to return to normal levels compared to the obese-diabetes control group (OB STZ). The serum cholesterol and triacylglycerol levels of all the diabetic groups after the injection of STZ increased significantly compared to the OB control group. However, during the treatment with metformin, the levels continuously declined, and following the 4 weeks of the metformin treatment period, there was a significant reduction in metformin compared to the OB and ND control groups. The evaluation of the amelioration of metformin on diabetes was tested by blood glucose and serum creatinine. As shown in Fig. 6 , metformin reduces the blood glucose and serum creatinine of obese-diabetic rats, which suggests its ability to regulate type 2 DM symptoms and its complications as well as to possibly have a protective effect on DM.
Metabolic pathway analysis of diabetic models
The metabolic pathways and the mechanisms involved in DM are significant aspects to understand the complications of this disease prior to untargeted metabolomics. Potential biomarkers are useful for extracting out the desired information about DM and its metabolic and biochemical disturbances. The MetPA coupled with METLIN and KEGG are capable of performing pathway analyses. From the results, the synthesis and degradation of ketone bodies' pathway showed the highest impact value, followed by taurine and hypotaurine metabolism and glyoxylate and dicarboxylate metabolism. The pathway analysis was proposed to show the metabolic pathways among the significantly affected metabolites associated with normal-and obese-diabetic conditions (Fig. 7) .
After the treatment period at week 17, the metabolite variation for normal and obese diabetes was observed as compared to ND. However, by comparing the normal-and obesediabetic groups, there was an obvious difference, which suggests that both of these groups have some features that associated with their unique metabolic syndromes. The normaldiabetic rats exhibited higher glucose than obese-diabetic rats. This might be due to the production of energy in biological systems is highly correlated to glucose metabolism. This process involves the catabolizing of glucose through glycolysis into pyruvate, which might be transformed to acetyl-CoA via pyruvate. Consequently, the synthesis and utilization of ketone bodies are elevated as shown by normal-diabetes model [10, 27] . In comparison, our results revealed a decrease in ketone bodies in the obese-diabetic group. The levels of β-hydroxybutyrate, acetoacetate, and total urine ketone bodies of normal-diabetic rats were significantly higher as compared to obese-diabetic ones, which supported by a previous study on ketone bodies in type 1 and 2 diabetic rats. The ketone bodies are known to be the biomarkers for type 1 DM (insulin-dependent) [18, 20] . The determination of the level of urine ketone bodies is important for the identification of type 1 DM. Thus, it can be suggested that normal diabetes and obese diabetes mimic the type 1 and 2 DM conditions and complications, respectively.
The tricarboxylic acid (TCA) cycle is defined as a process that converts acetyl-CoA into energy in the presence of carbon dioxide in the mitochondria. These processes take place in all aerobic organisms by a series of chemical Fig. 6 The biochemical parameters of rat serum for diabetic groups compared to controls. a,b,c,d,e,f Each letter above the columns indicates that the results showed statistically significant (P < 0.05) differences reactions to generate energy in the form of adenosine triphosphate (ATP), achieved via the oxidation of the acetate derived from proteins, carbohydrates, and fats. Additionally, the catabolic function of the TCA cycle is also involved in other metabolic pathways, in part in the synthesis of amino acids, fatty acids, and gluconeogenesis. The metabolites succinate, 2-oxoglutarate, citrate, and fumarate are the intermediates of TCA; it was observed that they decrease in both the obese and obese-diabetic groups in this study (Fig. 7) . Dimethylamine and trimethylamine are the components present in the urine that are derived from the dietary choline metabolism that is catalyzed by gut bacteria. One of the metabolites released from dietary phosphatidylcholine and present in high-fat foods is choline. The decrease in the concentration of alanine in the obese-diabetic rats suggested that it is degraded into pyruvate and potentially used as the substrate for gluconeogenesis.
Conclusion
The biochemical and metabolic parameters showed varied changes among normal, normal-diabetic, obese, and obese-diabetic rats. The obesity and DM inductions were also verified and the treated rats showed weight stability or modest weight loss. The S-and SUS-plots were useful in identifying the biomarkers of ND, normal-diabetic, OB, and obese-diabetic groups. There was metabolic disorder in carbohydrate, amino acids, and lipid metabolisms upon diabetes induction. The ketone bodies were significantly higher in normal-diabetic rats compared to obese-diabetic ones at week 17. The longterm complications for normal diabetes were more pronounced than the obese diabetes. In addition, the suggested metabolic pathway has revealed possible correlations between the normal-diabetic and obese-diabetic conditions. The obese-diabetic rats displayed a drop in blood glucose and an improvement in the metabolic disorder of lipids and other biochemical parameters upon treatment with metformin, which seemed to be better than normal-diabetic rats. These findings suggest that metformin may provide better improvement for DM complications and insulin sensitivity for obese diabetes rather than normal diabetes. These findings suggest that normal diabetes is similar to the type 1 DM model, and obese diabetes is similar to the type 2 DM model. Metabolic pathway analysis in normal-(ND STZ) and obesediabetic (OB STZ) rats. By comparing normal-and obese-diabetic rats, the metabolites highlighted with green are higher in normal-diabetic rats compared to obese-diabetic rats and the blue highlighted ones are for those higher in obese-diabetic rats mechanisms, such as regulating pyruvate metabolism, controlling hyperglycemia, and decreasing hepatic glucose production. In addition, several connections in metabolites between OB, and both diabetic models were also highlighted, which emphasizes the link between obesity and DM. It is significant to investigate this matter as it can provide useful information. Furthermore, this research also succeeded to identify numerous pathways and metabolism aspects shared by OB and obese-diabetes models. The results from this study are with great benefit in the research of targeted drugs of DM.
